Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Filings Soon As Biogen Snaps Up Ionis' Antisense Treatment

Executive Summary

Promising top-line Phase III data have prompted Biogen to exercise an option to develop and commercialize Ionis's novel antisense treatment nusinersen for infantile-onset spinal muscular atrophy; filings are due shortly.

You may also be interested in...



One Way To Get Ahead: Biogen To Test Spinraza Given After Novartis’s Zolgensma

Biogen said some spinal muscular atrophy patients are currently being treated with Spinraza after receiving the Novartis gene therapy – its main competitor – so it will start a study of the risk/benefit in 2021.

Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016

Analysts expect strong uptake for the antisense oligonucleotide (ASO) given the high unmet need in SMA and positive data in multiple studies, while the first ASO approved this year – Sarepta’s Exondys 51 – has seen some pushback from payers despite the lack of DMD therapies.

Biogen/Ionis’ Spinraza Data Shows Opportunity For Broad SMA Label

Both companies’ stocks surged Nov. 7 on positive data from a second Phase III trial showing the antisense drug improved motor function in children with later onset spinal muscular atrophy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel